A phase 1 dose-escalation study of the safety and pharmacokinetics of XL418 administered orally daily to subjects with solid tumors

Trial Profile

A phase 1 dose-escalation study of the safety and pharmacokinetics of XL418 administered orally daily to subjects with solid tumors

Suspended
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2008

At a glance

  • Drugs XL 418 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Exelixis
  • Most Recent Events

    • 09 Jan 2008 Status changed from recruiting to suspended.
    • 21 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top